Apollo Endosurgery Inc
F:HQ8F
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
A
|
Apollo Endosurgery Inc
F:HQ8F
|
432.7m EUR |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
198.9B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
176.3B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
148.2B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
126.2B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
113B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
46.7B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
50.8B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
50.1B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
50.5B USD |
Loading...
|
|
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
36.6B USD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Apollo Endosurgery Inc
Glance View
Apollo Endosurgery, Inc. is a medical technology company, which focuses on the design, development, and commercialization of medical devices to advance gastrointestinal therapeutic endoscopy. The company is headquartered in West Lake Hills, Texas and currently employs 107 full-time employees. The company went IPO on 2005-04-21. The firm develops and distributes devices that are used by surgeons and gastroenterologists for various procedures related to gastrointestinal conditions including closure of gastrointestinal defects, managing gastrointestinal complications and the treatment of obesity. The firm's products include the OverStitch Endoscopic Suturing System, which enables advanced endoscopic procedures from within the Gastrointestinal tract, or endolumenally, by allowing physicians to suture, especially full-thickness, and secure the approximation of tissue. The X-Tack Endoscopic HeliX Tacking System is a suture-based device designed specifically for closing and healing defects in the lower gastrointestinal tract. The Orbera Intragastric Balloon System is a non-surgical alternative for interventional weight loss.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
Over the last 3 years, Apollo Endosurgery Inc’s Gross Margin has increased from 50.6% to 55.2%. During this period, it reached a low of 48.8% on Jun 30, 2020 and a high of 56.4% on Jun 30, 2022.
